Table 2.
Tumor and Proliferation Markers in High-Grade Serous Carcinoma (HGSC) vs. Other Epithelial Ovarian Tumorsa
| HGSC |
Other Tumorsa |
P | |||
|---|---|---|---|---|---|
| (n = 26) |
(n = 43) |
||||
| n | % | n | % | ||
| Tumor marker | |||||
| p53b | 24 | 92.3 | 10c | 23.8 | <.001 |
| p16d | 26 | 100 | 26 | 60.5 | <.001 |
| Proliferation marker | |||||
| Ki67e | 19 | 73.1 | 16 | 37.2 | <.005 |
Other tumors = endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, low-grade serous carcinoma, carcinosarcoma, mixed tumor, non-differentiated carcinoma, mucinous cystadenoma and borderline ovarian tumor.
Tumors were scored with respect to distribution (0-4) and intensity (1-3) of immunoreactivity. An immunohistochemical composite score was calculated by multiplying the distribution and intensity scores (0-12). Score 0 and 12 were considered as p53 mutation.
One case was not evaluated due to technical problems with immunohistochemical staining.
>25% Moderat/intense diffuse nuclear staining was considered as p16 mutation.
High Ki67 proliferation (> 25% stained cells).